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ABSTRACT 
Interferons (IFNs) were first described in the 1950’s and has since been characterized as 
potent inducers of pathogen defense mechanisms. Since then, researchers have uncovered a 
depth of mechanisms in the IFN system extending beyond immune modulation of pathogen 
defense. IFNs have been described to play a role in the control of cell homeostasis as well as 
contributing to both the natural defense against cancer and cancer progression. 
The objective of the work performed in this thesis was to understand how type I IFNs are able 
to contribute to such a wide range of biological processes and to investigate metastatic 
progression of malignant melanoma. We first performed screens of miRNAs on sorted 
immune cells from patients treated with IFNβ. We identified miR-31-5p to be downregulated 
in T cells of patients treated with IFNβ. miR-31-5p was also decreased in patients with 
autoimmune disease, characterized by an IFN signature, further proving type I IFN regulation 
of miR-31-5p expression levels. We were able to show that miR-31-5p regulate metabolism 
of CD4+ T cells. In an attempt to get new insights into IFNAR1 signaling, we applied 
proximity proteomics techniques to IFNAR1. Labeled proteins were extracted and 
subsequently analyzed using quantitative mass spectrometry. We successfully generated 
interactome data that revealed insights to a possible nuclear translocation mechanism of 
ligand bound IFNAR1. 
Bromodomain (BRD) proteins are chromatin bound proteins that regulate a multitude of 
processes important in transcriptional regulation and epigenetic regulation of gene 
expression. Several BRD proteins regulate the expression of type I IFN genes and are 
emerging targets for new cancer drugs. We therefore aimed to identify BRD proteins that 
play a role in metastatic progression and plasticity of malignant melanoma. We identified that 
the BRD protein TRIM28 controls a plasticity switch of melanoma cells through expression 
of JunB. Plasticity switching of melanoma cells represent a model of metastatic progression. 
Recently, the role of ER stress in both protecting and killing tumors has been highlighted. We 
therefore aimed to identify new small molecules capable of inducing strong ER stress. We 
identified the IFN-inducing small molecule IMQ as a potent ER stress inducer in melanoma 
cells independently of TLR7/8 expression. ER stress induced by IMQ in melanoma cells lead 
to cell death and represents a possible pharmaceutical strategy to target and kill cancer cells.  
In summary, our studies provide insights to type I IFN driven mechanisms with implications 
for autoimmune disease and cancer. 
 
 
 
  
   
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Interferon (IFN) är en grupp av signaleringsmolekyler som kallas för cytokiner och 
upptäcktes för första gången på 1950-talet. Upptäckten att denna grupp proteiner kunde 
hjälpa celler att bekämpa infektioner gav denna grupp namnet interferon, efter det engelska 
ordet ”interfere”. Forskare har under åren som gått sedan den första upptäckten karaktäriserat 
IFN-familjen och dess funktioner. Sammanfattningsvis så fungerar denna familj av cytokiner 
som en potent signaleringsmolekyl för immunförsvaret vid upptäckten av en infektion. 
Immunceller svarar på IFN genom att producera faktorer som hjälper immunförsvaret att 
bekämpa infektionen. Denna grupp av cytokiner kan delas in i tre grupper baserat på deras 
funktion och struktur, typ I, II och III. Typ I IFN kan produceras av de allra flesta celler i 
kroppen som en respons av virus- och bakterieinfektioner. Stora mängder typ I IFN kan även 
produceras av specialiserade immunceller. Dessa cytokiner fungerar alltså som 
immunreglerande signaleringsmolekyler. Forskning på IFN har visat att deras roll i 
människans biologi sträcker sig längre än immunreglering. Det har visat sig att cytokinerna 
både bekämpar och i viss mån bidrar till utvecklingen av vissa cancerformer, det har även 
visat sig att de bidrar till uppkomsten av autoimmuna sjukdomar och reglerar viktiga cellulära 
funktioner. 
Målet med forskningen i denna avhandling var att kartlägga mekanismer bakom typ I IFN 
som bidrar till dess komplexa funktioner, samt att studera den metastatiska processen av 
malignt melanom.   
I den första studien studerade vi patienter behandlade med IFN, före och efter behandling. 
Celler från dessa patienter isolerades och analyserades för deras uttryck av mikro RNA 
molekyler. Vi fann att T celler från patienter behandlade med IFN uttrycker lägre nivåer av 
mikro RNA-31 efter behandling. Vidare identifierade vi att mikro RNA-31 reglerar 
energimetabolismen i T celler, vilket har stor betydelse för T cellernas kapacitet att bekämpa 
infektioner. I den andra studien studerade vi receptorn för typ I IFN med avsikt att kartlägga 
alla de protein-interaktioner som uppstår intra-cellulärt efter att receptor bundit till IFN. Vi 
utvecklade nya metoder för identifiering av protein-interaktioner för receptorer och 
identifierade tidigare okända interaktionspartners för IFN-receptorn. 
Malignt melanom kopplades tidigt ihop med IFN där cytokinerna har använts i 
behandlingssyfte. I den fjärde studien studerade vi den metastatiska processen för malignt 
melanom. Vi upptäckte att höga nivåer av proteiner TRIM28 kunde kopplas till kortare 
överlevnad för patienter diagnostiserade med metastatisk melanom. Vi visar även att TRIM28 
kontrollerar kritiska mekanismer för genuttryck i melanom-celler. Genreglering av TRIM28 i 
melanom-celler kontrollerar cellernas förmåga att metastasera och växa. Slutligen så visar vi i 
den tredje studien hur den IFN-inducerande molekylen, imiquimod, har förmågan att binda 
till melanom-celler och döda cellerna genom att inducera intracellulär stress. 
Sammanfattningsvis så presenterar arbetet i denna avhandling nya insikter i hur typ I IFN kan 
påverka autoimmuna sjukdomar samt cancer. 
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1 INTRODUCTION 
Interferons (IFN) were first reported in 1954 as an “inhibitory factor” by Nagano and Kojima, 
discovered in the skin of inoculated rabbits (Nagano and Kojima, 1954). The cytokines were 
first named by Isaacs and Lindenmann in 1957 for their capacity to “interfere” with viral 
infections (Isaacs and Lindenmann, 1957). Over several decades, researchers have uncovered 
a depth of mechanisms in the IFN system. Different types of IFNs have been characterized 
and their regulation and role in immunity have been elucidated. The role of IFNs in 
modulating immunity and contributing to disease have been studied for a long time. In later 
years, emerging studies have revealed complex mechanisms of interferons describing their 
roles in early development and controlling cell homeostasis.  
  
1.1 TYPE I INTERFERONS 
IFNs are divided in to three types (I-III). The type I IFN gene family consist of IFNα, IFNβ, 
IFNε, IFNκ and IFNω. The IFNα family consist of at least 13 genes in humans while only 
one single gene exist for IFNβ (Honda et al., 2006). Type II IFNs consist of IFNγ and are 
produced mainly by NK cells and T cells in response to viral and bacterial infections and 
activate a broad range of immune cells. Type III IFNs consist of IFNλ1, IFNλ2 and IFNλ3. 
They act mainly on the mucosal epithelial cells to  protect maintain healthy mucosal surfaces 
(Wack et al., 2015). The type I IFN system has developed evolutionary as a natural defense 
mechanism against viral infections. All vertebrates have genes encoding both IFNα and IFNβ 
in their genome (Stetson and Medzhitov, 2006). The existence of type I IFNs throughout the 
vertebrate lineage signify the evolutionary importance of the type I IFN system.   
 
1.1.1 Production and regulation of type I IFNs 
Type I IFNs can be produced and secreted by all nucleated cells. However, the main 
producers of IFNα are plasmacytoid dendritic cells (pDCs) and they are often referred to as 
natural IFN producers. Type I IFNs are produced in response to microbial infection mainly 
through recognition of pathogen-associated molecular patterns (PAMPs) by the pattern 
recognition receptors (PRRs). 
Toll-like receptors (TLRs) 
TLRs are PRRs mainly expressed by specialized immune cells and recognize different types 
of extracellular PAMPs. All TLRs recognize extracellular PAMPs, either on the cell surface 
or in endosomes. Some TLRs are expressed mainly in endosomes such as TLR3, TLR7 and 
TLR9 while other are expressed on cell surfaces, such as TLR4. However, TLR4 is also 
found in endosomes after internalization upon lipopolysaccharide (LPS) recognition (Kagan 
et al., 2008). TLR4 is expressed in conventional DCs and macrophages (Takeuchi et al., 
1999). TLR3 responds to double-stranded RNA while TLR7 and TLR8 recognizes single-
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stranded RNA (Alexopoulou et al., 2001; Heil et al., 2004). TLR9 recognizes unmethylated 
CpG motifs of DNA and is expressed by pDCs, together with TLR7 they represent the main 
sensory mechanisms for the natural IFN producers (Lund et al., 2003). All TLRs contain an 
intracellular Toll-IL-1 receptor (TIR) domain. The TIR domain signals via recruitment of 
differentiation primary response gene 88 (MyD88) for all TLRs except for TLR3 which 
signals via TIR domain containing adaptor-inducing IFN (TRIF). TLR4 signals via both 
MyD88 and TRIF (Akira et al., 2006). Activation of MyD88 by TLR4 occurs at the cell 
surface while TRIF activation by TLR4 occurs upon internalization. Signaling by TLRs via 
either TRIF or MyD88 leads to activation of interferon regulatory factors (IRF). The IRFs are 
a family of transcription factors with well conserved DNA binding sites recognizing 
interferon-stimulated response elements (ISRE) (Darnell et al., 1994; Honda and Taniguchi, 
2006). MyD88 activates IRF7 and TRIF activates IRF7 via TANK-binding kinase 1 (TBK1). 
Activated IRF3 and IRF7 lead to expression of type I IFNs and they are key transcription 
factors for type I IFN production (Honda et al., 2005; Sakaguchi et al., 2003). 
Cytosolic PRRs 
As opposed to TLRs, that recognize extracellular PAMPs, cytosolic recognition of PAMPs 
occur through cytosolic PRRs. While TLRs are mainly expressed by specialized cells, 
cytosolic PRRs are expressed by all nucleated cell. Of the cytosolic PRRs leading to type I 
IFN production, two well described RNA sensors are retinoic acid-inducible gene I (RIG-I) 
and melanoma differentiation-associated gene 5 (MDA5). Both contain caspase activation 
and recruitment domains (CARD). Both receptors are activated by viral nucleic acids but 
recognizes different types of dsRNA (Kato et al., 2006). Upon activation, the RIG-I and 
MDA5 recruits mitochondrial antiviral signaling (MAVS) that leads to a signaling cascade 
resulting in activation of mainly IRF3 or nuclear factor κB (NF-κB) (Yoneyama and Fujita, 
2009). In addition to cytosolic RNA sensors, pathogen-derived cytosolic DNA is identified 
by cyclic GMP/AMP synthase (cGAS). Activation of cGAS leads to production of cytosolic 
guanosine monophosphate-adenosine monophosphate (cGAMP), in the presence of GTP and 
ATP, which in turn triggers stimulator of interferon genes (STING). Activation of STING 
results in either IRF3 or NF-κB activation (Ishikawa and Barber, 2008; Sun et al., 2013). 
IFNα expression can only be induced through IRF activation while IFNβ expression can be 
induced by both IRFs and NF-κB (Ryals et al., 1985; Sato et al., 1998a; Sato et al., 1998b). 
IFNα production is therefore predominantly produced by pDCs that express high levels of 
IRF7 and TLR7 while IFNβ production is more widespread. 
 
1.1.2 Type I IFN signaling 
IFNα and IFNβ signals via the same cell surface receptor, the IFNα receptor (IFNAR). 
IFNAR is a heterodimeric receptor that consist of the subunits IFNAR1 and IFNAR2 (Novick 
et al., 1994; Uze et al., 1990). Type I IFN engage with IFNAR, leading to dimerization of the 
receptor subunits and activation of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), 
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resulting in phosphorylation of the receptor (Wilks, 1989). Signal transducer and activator of 
transcription (STAT) proteins are recruited and phosphorylated by the receptor (Fu et al., 
1992; Schindler et al., 1992). STAT phosphorylation leads to dimerization and translocation 
to the nucleus (Levy and Darnell, 2002; Stark and Darnell, 2012). STAT dimerization can 
differ and the combinations result in separate gene activation patterns. Canonical type I IFN 
signaling results in STAT1-STAT2 heterodimerization and complex formation with IRF9 to 
generate the interferon-stimulated gene factor 3 (ISGF3) (Levy et al., 1988). ISGF3 
recognizes and bind genes with ISRE sites. In contrast, STAT1 homodimers bind and induces 
expression of genes containing gamma-activated sequences (GAS), typically a hallmark of 
IFNγ signaling. STAT3 homodimers are also known to be formed as well as activation more 
STATs (Darnell et al., 1994; Ivashkiv and Donlin, 2014). The components of canonical type I 
IFN signaling are broadly expressed and most cells can mount a response to type I IFNs. The 
STAT1 and IRF9 genes contain ISRE sites and are therefore induced by ISGF3 formation. 
Increased expression of STAT1 and IRF9 induces the response to type I IFNs through 
positive feed-back and cells are able to rapidly respond IFNs (Gough et al., 2012; Levy et al., 
1990; Wong et al., 2002).  
In addition to canonical IFNAR signaling via the JAK-STAT pathway, IFNAR also activates 
p38 mitogen-activated protein kinase (MAPK) (Li et al., 2004; Ramsauer et al., 2002) and 
phosphatidylinositol 3-kinase (PI3K) (Platanias et al., 1996; Uddin et al., 1997; Uddin et al., 
1995). It is clear that activation of more than one signaling pathway is critical for the type I 
IFN response, as no single signaling cascade is sufficient to mount a full antiviral response 
(Platanias, 2005). The context-dependent nature of the signaling cascades downstream of 
IFNAR is still not fully elucidated. Extensive research efforts will be required to understand 
the complexity of the type I IFN signaling and the downstream events that occur upon 
IFNAR activation.  
 
1.1.3 Regulation of IFNAR signaling 
The multiple signaling cascades activated by IFNAR upon ligand binding results in a diverse 
cellular response. Many response factors are regulators of the signaling activity, resulting in 
positive or negative feedback control.  
Positive regulation 
Augmented signaling was briefly mentioned in the previous section by IFN-induced 
expression of STAT1 and IRF9. Many more regulatory mechanisms of IFNAR signaling 
have been demonstrated. STAT1 and IRF9 expression is also induced by other 
immunomodulatory cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6) and 
IFNγ (Hu et al., 2002; Mitani et al., 2001; Venkatesh et al., 2013). These mechanisms allow 
responding cells to be primed for type I IFN response and augments the signal intensity. 
Signal augmentation also occurs via spleen tyrosine kinase (SYK) that mediates STAT1 
phosphorylation, an event that is dependent on activation of immunoreceptor tyrosine-based 
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activation motifs (ITAMs) (Tassiulas et al., 2004). These mechanisms are implemented to 
either amplify an existing signal or to prime cells for robust type I IFN responses. 
Negative regulation 
Type I IFN signaling induces expression of a number of negative regulators that limit the 
extent of IFNAR signaling in a negative feedback loop. Suppressor of cytokine signaling 
(SOCS) proteins 1 and 3 are IFN induced genes that bind to IFNAR to suppress activity of 
JAK (Yoshimura et al., 2007). Ubiquitin carboxy-terminal hydrolase 18 (USP18) is also an 
IFN induced gene and is capable of binding to IFNAR2, replacing JAK1 and reducing 
STAT1 phosphorylation (Sarasin-Filipowicz et al., 2009). IFNAR activity is also regulated 
by lysosomal degradation and endocytosis of IFNAR1 and IFNAR2 (Chmiest et al., 2016; 
Claudinon et al., 2007). Identification of new regulatory mechanisms of IFNAR signaling 
presents opportunities for pharmaceutical intervention to limit pathogenic IFNAR signaling. 
 
1.1.4 Type I IFN-induced transcription 
Type I IFN signaling leads to induction of a large set of genes. These are collectively referred 
to as IFN stimulated genes (ISGs). The Interferome (v2.01) classifies up to 2000 genes as 
ISGs while more stringent methods to identify ISG normally refer to >300 genes (Rusinova et 
al., 2013; Schoggins et al., 2011). These genes are involved in a wide range of biological 
functions such as anti-viral and anti-bacterial defense, cell proliferation, immune regulation 
and apoptosis. 
Transcriptional regulation 
Genomic accessibility and the epigenetic landscape are crucial for gene expression, and the 
expression of ISGs is no different. Induction of ISGs require genomic accessibility of the 
ISGF3. IRFs recruit histone acetyltransferases (HATs) that acetylates histones resulting in the 
opening up of nucleosome structures (Bell et al., 2011). This is performed by recruitment of 
the BRG1- or HBRM-associated factors (BAF) chromatin remodeling complex (Liu et al., 
2002). The bromodomain (BRD) containing protein SMARCA4 is recruited by ISGF3 upon 
type I IFN stimulation (Ni et al., 2005). The induction of ISGs at the transcriptional level is 
highly complex, SMARCA4 regulates only a subset of ISGF3-mediated expression of ISGs 
(Huang et al., 2002). Regulation of ISGs by SMARCA4 at the transcriptional level is only 
one of many mechanisms that control expression of ISGs. Acetylation of histones lead to 
recruitment of BRD4 that recruits the positive transcription elongation factor b (pTEFb) 
complex. The pTEFb complex is critical for transcription and elongation of RNA and can be 
potentially be targeted to reduce expression of inflammatory genes (Nicodeme et al., 2010; 
Patel et al., 2013). With the development of potent BRD inhibitors such as JQ-1 for BRD4 
(Meng et al., 2014). BRDs have emerged as lucrative targets to alter expression of ISGs in 
inflammatory diseases (Klein et al., 2016).  
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Small non-coding RNAs 
microRNAs (miRNA) are small non-coding RNAs that function as post-transcriptional 
regulators of gene expression. Many miRNAs regulate the type I IFN response (David, 2010). 
Reduction miR-155 leads to induced responsiveness of CD8+ T cells to type I IFN by 
regulating STAT1 mRNA (Gracias et al., 2013). Another miRNA with suppressive functions 
is miR-146a that downregulates STAT1 in Th1 cells  (Lu et al., 2010). Responsiveness to 
type I IFN can also be regulated by miR-29a mediated degradation of IFNAR1 mRNA 
(Papadopoulou et al., 2011). In all, the role of miRNAs in the type I IFN system is a growing 
field and can help to explain the context dependent-differences in type I IFN signaling. 
 
1.1.5 Autoimmunity and interferons 
Autoimmune diseases constitute a large family of complex diseases including systemic lupus 
erythematosus (SLE) and primary Sjögren’s syndrome (pSS). A common trait amongst these 
two diseases is the upregulation of ISGs, commonly referred to as an IFN signature (Baechler 
et al., 2003; Wildenberg et al., 2008). Strong evidence exists for the involvement of type I 
IFNs in systemic autoimmune diseases, e.g. treatment of patients with type I IFN against 
chronic viral infections and neoplasias can lead to the development of symptoms of 
autoimmune disease (Ronnblom et al., 1990; Schilling et al., 1991). Chronic exposure of high 
type I IFN levels shifts the immune system towards pathological functions that contribute to 
autoimmune diseases (Crow et al., 2015). Blocking IFNAR1 using the antibody Anifrolumab 
to reduce type I IFN signaling is an approach currently being assessed in clinical trials for 
SLE patients (Furie et al., 2017). Results from the phase II clinical trial of Anifrolumab were 
promising, although, early reports from the phase III clinical trial are less encouraging.  The 
role of type I IFNs in systemic autoimmune diseases is complex. Even though strong 
evidence exists for their contribution to the diseases, it remains unclear if therapeutic 
intervention in the signaling pathways will be successful. To understand the biology of type I 
IFN driven disease, further research must be performed on the underlying mechanism 
contributing to pathogenesis. 
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1.2 CANCER 
The immune system has been known to play a role in cancer for a long time. German 
researcher Wilhelm Busch discovered as early as 1868 that infection with erysipelas caused 
tumor shrinkage. Further evidence was reported in 1893 in a case report of 10 patients treated 
with erysipelas infections (Coley, 1991). These findings led to experiments where patients 
with bladder cancer were treated intradermally with Bacillus Calmette-Guerin in 1976 
(Morales et al., 2017). The concept of immune surveillance of tumors was proposed in 1970 
(Morales et al., 2017) and has been widely accepted and included as a hallmark of cancer 
(Hanahan and Weinberg, 2011). IFNs were reported in 1984 to have anti-neoplastic effects 
after intra muscular injections to patients with hairy-cell leukemia (Quesada et al., 1984). 
Clinical trials to treat metastatic melanoma patients with recombinant IFNα showed moderate 
overall response rates (Creagan et al., 1986). IFNα was then used in clinics as an adjuvant for 
patients with malignant melanoma post-surgery showing improved overall survival (Tarhini 
et al., 2012). 
 
1.2.1 Malignant melanoma 
Cutaneous malignant melanoma is a cancer originating from melanocytes in the skin. 
Mutations in malignant melanoma are mainly caused by UV radiation. The high exposure to 
UV in the skin makes malignant melanoma the most mutated form of cancer (Alexandrov et 
al., 2013; Lawrence et al., 2013). Some of the most common mutations in melanoma are 
mutations in the BRAF, NRAS and PTEN genes. A study performing whole-exome 
sequencing of 121 melanoma tumors identified BRAF mutations in 90/121 samples, NRAS 
mutations in 33/121 samples and PTEN mutations in 16/121 samples. Only 16/121 samples 
were free of either BRAF or NRAS mutations (Hodis et al., 2012). The high mutation 
frequency of BRAF and NRAS is a common recurrence in melanoma studies (Krauthammer et 
al., 2012; Zhang et al., 2016). BRAF mutations were reported in >50% of all melanoma 
patients from the large genome-wide sequencing effort of The Cancer Genome Atlas (TCGA) 
(Cancer Genome Atlas, 2015; Guan et al., 2015).  
The BRAF and NRAS genes encode the Raf and Ras kinases, both critical for MAPK 
signaling. Ras acts upstream of Raf and is activated by many receptor tyrosine kinases 
(RTKs). Raf activation by Ras results in phosphorylation, activation and nuclear translocation 
of extracellular signal–regulated kinases 1/2 (ERK1/2) (Mendoza et al., 2011; Vojtek et al., 
1993; Zhang et al., 1993). The common BRAF and NRAS are activating mutations resulting in 
constitutive active MAPK signaling. The most common alteration to BRAF is the V600E 
mutation (Cancer Genome Atlas, 2015; Hodis et al., 2012). Phosphatase and tensin homolog 
(PTEN) is the protein encoded by the third most common mutation gene mutation in 
melanoma. PTEN acts as a negative regulator of PI3K signaling and loss-of-function 
mutations results in increased PI3K signaling. The identification of mutations in these 
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pathways have led to major efforts in identifying potent inhibitors by the pharmaceutical 
industry. 
Clinical overview of malignant melanoma 
According to statistics from the American Cancer Society the 5-year survival rate for patients 
diagnosed with stage I malignant melanoma is >90%. The survival rates for patients with 
metastatic melanoma is much worse with estimates as low 5-19% 5-year survival for stage IV 
patients (Sandru et al., 2014). The introduction of kinase inhibitors targeting the Ras-Raf 
pathway have been shown to be effective in targeting melanoma tumors. However, tumors 
develop resistance already within 6-8 months of the initiation of the treatment (Long et al., 
2014; Long et al., 2015). Combination of multiple inhibitors increases efficacy but can only 
delay the onset of resistance temporarily (Robert et al., 2015a). The discovery of immune 
checkpoint blockade inhibitors offers further treatment options for patients with metastatic 
melanoma. Many patients do not respond to immune checkpoint blockade therapy with 
response rates reported between 40-65% (Larkin et al., 2017; Robert et al., 2015b; Schachter 
et al., 2017). Like with kinase inhibitors, melanoma tumors develop resistance to checkpoint 
blockade therapy (Gide et al., 2018; Zaretsky et al., 2016). Another promising group of 
inhibitors for melanoma are the bromodomain (BRD) inhibitors with multiple clinical trials 
undergoing (Perez-Salvia and Esteller, 2017). These will undoubtedly add to the growing 
number of treatment options for malignant melanoma. 
The recent discoveries of novel inhibitors and therapies have improved the outlook for 
patients with metastatic malignancies. But moderate response rates and resistance 
mechanisms present major challenges to overcome metastatic progression of the disease. 
 
1.2.2 Phenotype switching of melanoma 
Survival rates for patients with melanoma decrease significantly for patients with metastatic 
disease. The main cause of death of melanoma is not the primary tumor but dissemination of 
metastatic tumors to distal organs. For cancer cells to disseminate from a primary tumor to 
form a metastasis, cells need to invade local tissue at the primary tumor site to access either 
blood or lymph vessels. This process is referred to as epithelial-mesenchymal transition 
(EMT) (Thiery et al., 2009). Metastatic cells need to survive in the circulation and extravasate 
from the blood vessel into new tissue. Finally, metastatic cells need to adapt to the new 
environment and proliferate. The reversed EMT process is usually referred to as 
mesenchymal-epithelial transition (MET). The metastatic process is initiated in melanoma as 
the primary tumor begins a vertical growth phase (Clark et al., 1984).  
EMT in epithelial cancers is driven by the expression of proteins such as TWIST, SNAIL, 
ZEB1/2 that repress E-cadherin expression and promote a mesenchymal-like cell state 
(Thiery et al., 2009). With regards to expression of EMT factors, research groups have shown 
conflicting results in melanoma (Caramel et al., 2013; Denecker et al., 2014). Melanoma is 
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not an epithelial cancer and is not driven by classical EMT. Furthermore, the metastatic 
process of melanoma is not driven by acquisition of new mutations but rather seem to be 
driven by a high degree of plasticity (Falletta et al., 2017). It has been suggested that 
metastases of melanoma are formed by seeding of rare cancer stem cells (CSC) (Nguyen et 
al., 2012). Reports of subpopulations of melanoma with stem cell like properties first 
emerged in 2005 (Fang et al., 2005; Frank et al., 2005). However, these early reports have 
later been questioned and the proposed model of tumors seeded by CSC seem to not play a 
major role in metastatic formation of melanoma (Brinckerhoff, 2017; Cheli et al., 2014; 
Croteau et al., 2013). 
Melanoma plasticity 
Tumor heterogeneity can be described by several models. The CSC model where a small 
amount of stem-cell like cells in a tumor has the capacity to drive tumor progression (Nguyen 
et al., 2012; Reya et al., 2001). The CSC maintain self-renewal capabilities and the bulk of 
the tumor is made up of differentiated CSC that make up the intra-tumoral heterogeneity. 
Metastases are formed by seeding of CSC making up the inter-tumoral heterogeneity. 
Another model described is the clonal evolution model which is driven by genetic mutations 
and a clonal selection driving tumor progression (Nowell, 1976). Both these heterogeneity 
models represent unidirectional tumor progression and genetic heterogeneity. A third model 
is the bidirectional phenotypic plasticity model which suggests that cancers cells can undergo 
rapid phenotypic switching driven by reversible transcriptional and epigenetic changes. It has 
become apparent that melanoma cells are characterized by a high degree of plasticity and 
alternate between invasive and proliferative states (Hoek et al., 2008; Kim et al., 2017). To 
fully understand the metastatic process of melanoma, it is crucial to identify the factors 
controlling the phenotypic plasticity. 
 
1.2.3 ER stress and cancer 
Endoplasmic reticulum (ER) stress is a physiological response to events such as abundance of 
misfolded proteins or protein overload in the ER. To restore the protein homeostasis, ER 
stress triggers activation of the unfolded protein response (UPR) pathway (Maurel et al., 
2015). The UPR pathway is mediated by three ER membrane bound sensory proteins, 
inositol-requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and protein 
kinase RNA-like ER kinase (PERK) (Maurel et al., 2015). ER stress leads to IRE1-dependent 
splicing of Xbox binding protein 1 (XBP1), as well as phosphorylation of PERK and 
proteolytic cleavage of ATF6. These events lead to expression of ER stress induced genes 
such as DDIT3, ERDJ4, GRP78 and EPT1 (Walter and Ron, 2011). 
Moderate levels of ER stress have been shown to protect cancer cells and increase their 
capacity to survive in nutrient deprived environments, mainly through XBP1 promoted 
expression of hypoxia driven gene signatures (Chen et al., 2014). ER stress has also been 
shown to negatively impact the anti-tumor immune response in T cells and DCs (Cubillos-
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Ruiz et al., 2015; Song et al., 2018). Meaning that moderate levels of ER stress lead to 
increased survival of cancer cells and a reduced anti-tumor immune response. However, high 
levels of ER stress have been shown to induce cell death (Maurel et al., 2015). The apoptosis-
inducing potency of high ER stress can be exploited to target and kill tumor cells (Fribley et 
al., 2004). A search for additional potent ER stress inducers that are effective against cancers 
is therefore lucrative to identify therapies. 
 
  
 10 
1.3 TRIM28/KAP1/TIF1b 
The tripartite-motif is a superfamily of proteins known as TRIMs that can be found in all 
metazoan animals (Ozato et al., 2008). The TRIM family contains 75 proteins (Versteeg et 
al., 2013) in humans and is characterized by the presence of the tripartite-motif that contains a 
RING domain, one or two B-box domains and a coiled coil domain, also referred to as the 
RBCC domain (Ozato et al., 2008). TRIM28, also known as KRAB domain-associated 
protein 1 (KAP1) or transcriptional intermediary factor 1 β (TIF1β), belong to a subclass of 
TRIMs together with TRIM24 (TIF1α), TRIM33 (TIF1γ) and TRIM66 (TIF1d). This 
subclass of TRIMs is characterized by their specific C-terminal motif that contains a PHD-
Bromodomain (PB) (Peng et al., 2002). BRD containing proteins are classified as epigenetic 
readers that typically bind to acetylated lysine on histones (Dhalluin et al., 1999; Haynes et 
al., 1992). BRDs represent a family of epigenetic proteins that have emerged as lucrative drug 
targets in cancer (Filippakopoulos and Knapp, 2014; Fujisawa and Filippakopoulos, 2017). 
We identified TRIM28 as a repressed gene in immune cells from patients with pSS (data not 
shown) and subsequently identified that TRIM28 plays a major role in malignant melanoma. 
 
1.3.1 Immune regulation by TRIM28 
It has been suggested that TRIM28 modulates innate immune signaling responses by 
interacting with multiple transcription factors involved in immune system regulation. One 
such report suggests that TRIM28 act as a negative regulator on IRF7 to modulate the type 
IFN and antiviral response (Liang et al., 2011), another study discovered that TRIM28 bind 
and interact in a similar fashion with IRF5 (Eames et al., 2012). TRIM28 has also been 
reported to interact with members of the STAT transcription factor family.  
In a screen of TRIM28-STAT interactions it was reported that TRIM28 binds with high 
affinity to STAT3 but also with lower affinity to STAT1. The same study showed that siRNA 
knockdown (KD) of TRIM28 potentiated the effect STAT3 mediated IL-6 stimulation of 
human cells in vitro (Tsuruma et al., 2008). STAT1 association to TRIM28 has also been 
reported in another study performed in human cells in vitro where KD of TRIM28 again 
potentiated the effect of type I IFN signaling (Kamitani et al., 2008). Interestingly it has been 
reported that closely related proteins TRIM24 and TRIM33 are associated with immune 
phenotypes related to the type I IFN system in mouse models (Ferri et al., 2015; Tisserand et 
al., 2011). Taken together, these reports indicate a role for TRIM28 in regulating innate 
immune functions. We have observed a reduction of TRIM28 expression in both patients 
with systemic autoimmune diseases, and in IFNβ treated multiple sclerosis patients. 
Therefore, the regulatory system involving type I IFN and TRIM28 requires further 
investigation. 
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1.3.2 TRIM28 in development and differentiation 
TRIM28 is a critical regulator of development and differentiation, however TRIM28 does not 
interact directly to DNA but through interaction with DNA-binding KRAB-domain 
containing zinc finger (ZNF) transcription factors as shown in 1996 by several independent 
reports (Friedman et al., 1996; Kim et al., 1996; Moosmann et al., 1996). Strong evidence for 
the critical role of TRIM28 in regulation of development was shown in 2000 by Cammas and 
Losson when they established that mice deficient in TRIM28 did not undergo gastrulation 
and that no surviving embryos was found at E8.5 (Cammas et al., 2000). Further evidence of 
TRIM28 importance in development comes from conditional knockout (cKO) mouse models 
where it has been shown that inactivation of Trim28 in the forebrain causes heightened levels 
of anxiety and alterations in learning (Jakobsson et al., 2008). It has also been shown that 
TRIM28 controls erythropoiesis by inactivating Trim28 in hematopoietic cells of adult mice 
and observing severe anemia (Hosoya et al., 2013). Studies of TRIM28 have also 
demonstrated a function of maintaining pluripotency of embryonic stem cells (ESCs) as well 
as being required for ESCs differentiation (Cheng et al., 2014; Rowe et al., 2013; Seki et al., 
2010). It is clear that TRIM28 plays a very important role in cell differentiation and 
proliferation and affects many aspects of cellular physiology and although exact mechanisms 
of how TRIM28 influences these functions is unclear there have been numerous findings over 
the past decade giving insight in to the functions of TRIM28. In the coming sections I will 
summarize some of the most important findings regarding the functions of TRIM28 that 
emphasizes how this protein is able to influence such wide range of cellular processes. 
 
1.3.3 TRIM28 as an epigenetic regulator 
Histone modifications and chromatin remodeling 
One of the most well described mechanisms of TRIM28 is the coordinated interaction with 
SET domain Bifurcated 1 (SETDB1) which is a methyltransferase that specifically 
trimethylates (me3) Lys-9 of histone H3 (H3K9). H3K9me3 functions as a tag to recruit the 
binding of HP-1 which in turns acts as epigenetic transcriptional repressor thereby silencing 
euchromatin regions (Schultz et al., 2002). The recruited HP-1 also binds directly to a HP-1 
binding domain on TRIM28 to form a highly effective euchromatin transcriptional repressive 
complex (Iyengar et al., 2011; Sripathy et al., 2006).  In addition to trimethylating H3K9, the 
PB domain of TRIM28 can also interact with Mi2α that can be found in the nucleosome 
remodeling and histone deacetylation (NuRD) complex that effectively recruits histone 
deacetylases (HDACs) (Schultz et al., 2002; Schultz et al., 2001). Acetylated histones are a 
mark of euchromatin and active transcription, HDACs effectively remove the charged acetyl 
group of the histone and heterochromatin is eventually formed. 
DNA methylation 
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In addition to histone modifications and chromatin remodeling TRIM28 has also been 
reported to be associated with genomic imprinting of DNA during embryogenesis by 
controlling DNA methylation. Studies have shown that TRIM28, through KRAB-ZNF 
recruitment, is able to induce cytosine methylation in murine ESCs. Interestingly, the same 
study shows that KRAB/TRIM28 methylation does not occur in differentiated cells but is 
established during early embryogenesis and maintained through development (Quenneville et 
al., 2012). Other studies have shown that TRIM28 interacts through specific KRAB/ZFP, 
ZFP57, with the DNA methyltransferase (DNMT) recruiting protein NP95 to maintain 
genomic imprinting (Zuo et al., 2012).  However, it is unclear what role TRIM28 plays in 
recruitment of DNMTs and since histone lysine methylations are involved in this process it 
will require further investigation to determine exactly how TRIM28 contributes to genomic 
imprinting. 
Transcriptional elongation 
One of the most important processes to affect gene expression is the control of transcription 
by the RNA polymerase II (RNAPII) complex. Classically there are three stages of 
transcription by RNAPII: initiation, elongation and termination. RNAPII promoter-proximal 
pausing is a mechanism where RNAPII is already recruited to the transcription start site 
(TSS) but remains paused in activity before initiating processive elongation (Bunch et al., 
2014). This mechanism enables RNAPII being able to be released and activated with 
unprecedented rate upon an activating signal. Investigation in to the regulatory mechanisms 
of RNAPII-pausing has identified a number of important factors of the RNAPII complex 
including NELF (negative elongation factor), POLR2M (DNA directed RNA polymerase II 
subunit), MYC and P-TEFb (positive transcription elongation factor)/CDK9 (Bunch and 
Calderwood, 2015). Intriguingly, a role for TRIM28 in control of RNAPII-pausing has been 
uncovered by screening for proteins bound to the pause site of the human gene HSPA1B in 
vitro (Bunch et al., 2014). Other researchers have shown that TRIM28 is crucial in recruiting 
7SK small nuclear ribonucleoprotein complex and delivering inactive P-TEFb kinase to 
RNAPII-paused promoters that are needed for RNAPII activation and elongation (McNamara 
et al., 2016). While TRIM28 seem to play a role in RNAPII-pausing, contradictory reports 
lead to questions on the exact function TRIM28 exerts on RNAPII-pausing. 
Repression of endogenous retroviruses 
Around 8-10% of the human and mouse genome consists of mobile genetic elements knows 
as endogenous retroviruses (ERVs) which are retroviruses that have been integrated in to 
germline cells of the infected host and are passed on to the offspring. Many ERVs contains 
sequences that can act as regulatory element and thus altering gene expression of the host 
genome (Jern and Coffin, 2008). TRIM28 has been shown to play an important role in 
silencing ERV expression during embryogenesis by inducing repressive histone marks as 
previously described. Recent research has demonstrated that ERV repression mediated by 
histone modifications by TRIM28 in murine neuronal progenitor cells (NPCs) effectively 
leads to altered transcriptional dynamics (Fasching et al., 2015). The report also showed that 
  13 
depletion of TRIM28 in ESCs causes activation of gene promoters nearby ERVs. The 
repression of ERVs by TRIM28 is effectively altering the expression dynamics of nearby 
genes and long noncoding RNAs (lncRNAs), which illustrates both the importance of ERVs 
in transcriptional regulation of embryogenesis but also the multitude of effects that TRIM28 
plays in development.   
 
1.3.4 TRIM28 in cancer 
With their broad range of cellular functions, it is not surprising that many TRIM proteins are 
associated to cancer progression. Some TRIMs, like TRIM19, are even involved directly to 
carcinogenesis by translocating to other genes generating fusion proteins that drive tumor 
progression (Cambiaghi et al., 2012).  
TRIM28 is associated to various forms of cancer 
TRIM28 is highly expressed in many forms of cancer and in many cases associated with 
more severe disease. Reports have linked high TRIM28 levels to poor outcome in both 
gastric and thyroid cancer (Martins et al., 2013; Yokoe et al., 2010) as well as being 
associated to aggressive forms of ovarian cancer and metastatic cervical cancer (Cui et al., 
2014; Lin et al., 2013). TRIM28 has also been shown to promote cell growth and 
proliferation of breast cancer (Addison et al., 2015). Adding to previous reports that TRIM28 
mediates degradation of p53 through E3 ligase activity (Doyle et al., 2010; Wang et al., 
2005), recent reports have identified TRIM28 as an E3 ligase for ubiquitination of AMP 
activated proteinase kinase (AMPK) (Pineda and Potts, 2015). The complex formation is 
stabilized by MAGE proteins and subsequently leads to proteasome degradation of AMPK. 
TRIM28 mediated degradation of AMPK was shown to regulate mTOR signaling as well as 
autophagy. Interestingly autophagy can also be induced by endoplasmic reticulum (ER) stress 
(Lee et al., 2015) and it has been shown that certain cancer drugs such as bortezomib and 
nelfinavir induce ER stress (Mathur et al., 2014; Takenokuchi et al., 2015). This raises the 
question whether or not TRIM28 mediated regulation of autophagy plays any role in 
sensitivity to such drugs. We have identified TRIM28 as highly expressed and associated to 
poor outcome in malignant melanoma. Taken together with previous reports of TRIM28 in 
tumor biology, it becomes clear that research is needed to determine the role that TRIM28 
plays in melanoma progression and to evaluate its potential as a drug target for novel cancer 
therapies. 
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2 AIMS 
The objective of the work performed in this thesis was to understand how type I IFNs are able 
to contribute to such a wide range of biological processes and to investigate metastatic 
progression of malignant melanoma.  
 
2.1 SPECIFIC AIMS 
 
Project I: To identify miRNAs regulated by type I IFNs and elucidate their role in immune 
cells. 
 
Project II: To get new insights into IFNAR1 signaling by interactome analysis. 
 
Project III: To identify TLR agonists capable of inducing ER stress in melanoma cells. 
 
Project IV: To understand the role of BRDs in metastatic progression and plasticity of 
malignant melanoma. 
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3 METHODOLOGICAL CONSIDERATIONS 
In the following section advantages and limitations of the methods used in project I-IV will 
be presented. For more detailed description of the methods used, please refer to the methods 
sections of each project. 
 
3.1 METABOLIC MEASUREMENTS IN HUMAN CD4+ T CELLS 
In project I, we first analyzed public RNA-seq data from mouse miR-31-/- CD8+ T cells and 
identified an altered expression of metabolic gene signatures. To determine the role miR-31 
plays in metabolism of human CD4+ T cells we performed metabolic measurements using a 
Seahorse XFe24 Extracellular Flux Analyzer. The measurements were performed on human 
CD4+ T cells transfected with a miR-31-5p inhibitor or a negative control inhibitor. 
Measurements were also performed on untransfected CD4+ T cells stimulated with IFNα. 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured 
in all experiments and normalized to cell count. All cells were activated using anti-CD3/anti-
C28 beads and supplemented with IL-2 for the duration of the experiments. 
The Seahorse XFe24 is well established for T cell work and is efficient in collecting data 
from multiple measurements from each well. However, the protocol used for metabolic 
measurements can be optimized for either OCR or ECAR quantification. In our setup we 
collected data from both OCR and ECAR measured simultaneously in each well using 
published protocols for OCR (Wu et al., 2016). The experiment therefor lacked optimal 
conditions for ECAR quantification. A limitation when performing Seahorse measurements is 
the large number of cells needed for each well and the need to include at least five technical 
replicates. Therefore we collected as much data as possible from each experiment with less 
consideration for optimized conditions. An alternative method to measure metabolic activity 
is to use an Oroboros oxygraphy. However, it restrict users by requiring even more cells per 
measurement compared to a Seahorse and is less established for us of primary cells. Less 
sensitive colorimetric assays to measure glycolysis may also be used. 
 
3.2 PROXIMITY PROTEOMICS USING BIOTIN LIGASES 
In project II and IV we aimed to identify the interactomes and IFNAR1 and TRIM28 
respectively. The most commonly used method to identify protein-protein interactions is co-
immunoprecipitation (Co-IP). When performing Co-IP, a cell lysate is prepared and often 
crosslinked before the addition of an antibody targeting your protein of interest. 
Subsequently, the antibodies bound to the protein of interest and its crosslinked interactors 
are then pulled down and washed for further analysis. In project II and IV we chose to use an 
antibody-free proximity labeling method using biotin ligases. To perform biotin ligase 
proximity labeling we cloned the cDNA sequence of IFNAR1 and TRIM28 in to retroviral 
expression vectors containing either the biotin ligase BioID2 or hBASU (Ramanathan et al., 
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2018; Roux et al., 2012). Cells were then transduced with the fusion protein expression vector 
and selected using puromycin. To perform the proximity labeling, biotin was added to the 
culture medium prior to cell lysis and streptavidin-biotin pulldown. Stringent washing was 
followed by analysis using LC-MS. 
All labeling of interacting protein by biotin ligases occurs in living cells, the protein being 
studied leaves a trace throughout the cell of biotin labeled interactors. This allows you to 
perform dynamic mapping of a full protein interactome compared to Co-IP which will only 
give you a snapshot of protein interactions. Some interactions identified by biotin ligases 
might only occur transiently and those will not be identified by Co-IP. To capture a large 
protein complex when performing Co-IP, it is often critical to crosslink cells prior to lysis. 
However, these protein complexes are very fragile and might be disrupted during antibody 
pulldown and subsequent washing steps. When using biotin ligases, we can determine the 
labeling radius of the ligase by introducing a linker of varying size, this allows the ligase to 
tag interactors of varying degree of proximity to the fusion protein. Once tagged all 
biotinylated proteins are bound using streptavidin-coated beads. Because the affinity between 
streptavidin and biotin is so high it allows for very stringent washing procedures minimizing 
any background proteins that may be bound to the beads. When performing Co-IP, you are 
relying on to the antibody specificity and affinity to its target to reduce background which is a 
major contributor to background noise. 
Finally, a major advantage using biotin ligases over Co-IP is the reduced impact of cellular 
localization to determine the interactome. For example, membrane bound proteins can be 
hard to extract using regular cell lysis methods and therefore performing Co-IP on such 
proteins represents a major challenge. Using biotin ligases, we were able to tag membrane 
bound receptor IFNAR1 with either BioID or hBASU and successfully identify its 
intracellular interactors.  
Using biotin ligase also comes with certain limitations compared to previous established 
methods. First and foremost a fusion protein is generated by adding a ligase of 233 aa in the 
case of BioID2 or 260 aa in the case of hBASU. It is possible that this fusion protein is 
limited in functions compared to the endogenous protein and it is therefore important to test 
functionality of the fusion protein where possible, and to make sure that the cellular 
localization is not altered. While biotin ligase labeling presents major advantages to identify 
large set of interactors it might be harder to distinguish between direct and transient protein 
interactions. Stable isotope labeling in cell culture (SILAC) was introduced to the culture 
medium prior to the experiments to label the protein fractions with either heavy or light 
isotopes of Lysine and Arginine. This allowed for quantification of the labeled protein 
fractions and to distinguish between common and rare interactions.  
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3.3 MEASURING ER STRESS 
In project III we screened a panel of TLR and NOD agonists to identify those able to induce 
ER stress in melanoma cells. To identify ER stress induced agonists, we used unconventional 
splicing of XBP1 mRNA as a marker for ER stress. During ER stress, 26 nucleotides (nt) are 
excised from XBP1 by activated IRE1. Spliced XBP1s can be discriminated from unspliced 
XBP1u by PCR on cDNA. Gel separation of the PCR product generates two bands with a 
26nt size difference, XBP1s and XBP1u. While PCR on XPB1 cDNA is an efficient method 
for screening purposes it does not allow for precise quantification of ER stress. 
An alternative method to identify ER stress is to quantify gene expression of ER stress target 
genes by qPCR. In project III we use CHOP, ERDJ5 and BIP as target genes for ER stress 
quantification. Other genes containing ER stress response elements or unfolded protein 
response elements in their promoter regions may also be used (Alger et al., 2011). As an 
alternative strategy to qPCR, induced ER target genes can be confirmed at the protein level 
by immunoblotting. Immunoblotting can also be used to detect phospho-eIF2a or XPB1s.  
 
3.4 GENOME WIDE CRISPR/CAS9 SCREENING 
As part of project III, we used a genome-wide CRISPR/Cas9 screen to try to identify the 
mechanisms whereby IMQ induces ER stress in cancer cells. We used A375 melanoma cells 
that lack expression of TLR7/TLR8 to identify an unknown IMQ receptor. 
To circumvent issues with fading Cas9 expression levels when using lentiviral vectors we 
first generated Cas9 expressing A375 cells using transposon integration. Stable Cas9 
expression was confirmed prior to lentiviral transduction of a genome-wide gRNA library 
(Sanjana et al., 2014). IMQ was added to the cells in an attempt to identify surviving clones 
of cells, surviving cells would be sequenced to identify any genes critical for IMQ actions. 
No surviving clones of cells were obtained, likely due to rapid shift in pH of the culturing 
medium caused by addition of IMQ. To circumvent the limitations of using IMQ in cell 
culture we planned to use the fluorescent properties to IMQ to perform a FACS based screen. 
Clones with lower IMQ intensity would represent a fraction of cells with reduced levels of 
IMQ receptors. 
 
3.5 GENE PERTURBATION WITH SHRNA AND CRISPR/CAS9 
In project IV we aimed to introduce genetic perturbations to examine the effect of TRIM28 
on melanoma cells. We decided to mainly use short hairpin RNA (shRNA) mediated KD. 
Using shRNA packed in to lentiviruses allows for efficient KD in cells generated in as little 
as 7 days post transduction, limiting any deviation to the parental cell line introduced by 
selection pressure. shRNAs are easily used in a different cell lines and allows for a 
comparison of KD effects in a multitude of cell lines efficiently. shRNAs also provide partial 
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loss-of function, similar to the effects of pharmaceutical inhibition. KO leads to complete 
loss-of function, which is hard to mimic using inhibitors and might not be suitable for studies 
to identify novel drug targets.  
The major limitations using shRNA KD is the possibilities of non-specific RNA degradation 
leading to unwanted off-target effect. To circumvent this, we used at least two different 
shRNA constructs to study the effect of TRIM28 KD. Alternative gene perturbation methods 
used in this project include CRISPR/Cas9 KO in A375 cells. KO clones were generated using 
lentiCRISPR_V2 (Sanjana et al., 2014) and single-cell sorted. KO were confirmed by 
immunoblotting. These cells were used to confirm key findings from shRNA experiments. 
However, by single-cell sorting cancer cells and expanding a single clone we risk introducing 
clonal differences compared to the parental cell line. In an attempt to avoid this, we 
performed CRISPR interference (Thakore et al., 2015) targeting TRIM28. We were not able 
to identify gRNAs with targeting efficiency comparable to the shRNA constructs used for 
TRIM28. 
 
3.6 CANCER MODELS 
To study the effect of TRIM28 on tumor growth in vivo in project IV we decided to use 
xenograft engraftment models. Immuno-compromised mice are engrafted with tumor cells of 
human origin most commonly through either subcutaneous or intravenous injection. 
Xenografts are widely used due to efficient engraftment of human cancer cells that can be 
treated with inhibitors or genetically modified prior to injections. Initial experiments were 
performed using a syngeneic mouse model. Trim28 KD B16.F10 were injected 
subcutaneously in to C57BL/6J mice and tumor size was measured. We proceeded to focus 
our efforts on xenograft models. 
To assess the effect of TRIM28 on both primary tumor growth and lung colonization we 
performed both subcutaneous and intravenous engraftments using TRIM28 KD cells. These 
experiments were complemented in vitro with a Matrigel transwell migration assay to 
examine the effect of TRIM28 on the migratory capacity of melanoma cell. With these three 
models we were able to study primary growth, colonization and migration of tumor cells 
upon TRIM28 KD.  
However, to study the role of TRIM28 in metastatic progression, a model is required where a 
primary tumor disseminates in to metastatic tumor growth. A model to study this is the 
tamoxifen induced BRafCA, PtenloxP, Tyr::CreERT2 (Dankort et al., 2009) crossed with 
Trim28 KO mice. A limitation is the timeframe of the extensive breeding required to succeed. 
Experiments to assess the clinical relevance of targeting TRIM28 in metastatic tumors would 
ideally be performed on established tumors. It is possible to use inducible shRNA constructs 
that would be induced when metastatic tumors are fully formed. This approach mimics 
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clinical settings where pharmaceutical intervention usual occurs after the formation of 
metastases. 
 
3.7 RNAPII-PAUSING BY CHIP-QPCR 
Proximity proteomics in melanoma cells identified multiple TRIM28 interactors that together 
form the RNAPII-pause complex. Previous reports have linked TRIM28 to RNAPII-pausing 
(Bunch et al., 2014; McNamara et al., 2016), however it remains unclear which role TRIM28 
plays in RNAPII-pausing. To study the role of TRIM28 in RNAPII-pausing in project IV, 
ChIP-qPCR was performed targeting RNAPII in A375 cells transduced with 
shSCRAMBLED or shTRIM28 lentiviruses. A375 cells were starved for 48 hours using 
serum free DMEM. Cells were then collected without or 30 minutes after addition of 10% 
serum followed by lysis and ChIP against RNAPII.  
By starving the cells of serum, RNAPII is accumulated at the TSS of RNAPII-pause 
regulated genes. The addition of serum then releases the complex and activates transcription. 
A pausing index was calculated by first performing qPCR targeting the TSS and gene body of 
RNAPII-pause regulated genes to quantify the occupancy of RNAPII. The abundance of 
RNAPII at the TSS was then divided by the abundance in the gene body (pause index). This 
method allows for measurement of RNAPII location along the gene, more RNAPII in the 
gene body indicates more transcription and less RNAPII-pausing. However, to accurately 
quantify transcribing RNAPII these experiments can be complemented by performing ChIP 
against phosphorylated RNAPII (pRNAPII).  
These methods are very efficient when studying selected genes in a multitude of cell 
conditions. For global gene analysis of RNAPII pausing it is possible to use global run-on 
sequencing (GRO-seq). In GRO-seq, the addition of sarkosyl inhibits the recruitment of 
additional RNAPII to TSSs, and the addition of labeled nucleotides (BrUTP) enables nascent 
RNA to be isolated using anti-BrdU antibodies. GRO-seq therefore allows for identification 
of recently transcribed RNA and makes it possible to map the position of transcriptionally 
engaged RNAPII (Core et al., 2008). By using GRO-seq in combination with inhibitors of 
RNAPII transcription initiation or elongation, it is possible to track the activity of RNAPII 
along the genome (Jonkers et al., 2014). Performing GRO-seq on cells with TRIM28 KD 
would have allowed for a global view of the effect of TRIM28 on RNAPII activity. 
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4 RESULTS AND DISCUSSION 
4.1 PROJECT I: MIR-31 REGULATES CD4+ T CELL METABOLISM 
Systemic autoimmune diseases are characterized by the upregulation of a large set of type I 
IFN regulated genes. It is still poorly understood how these genes contribute to autoimmune 
diseases such as pSS. In project I, we aimed to identify miRNAs regulated by type I IFNs and 
explore their role in autoimmunity. To identify miRNAs regulated by acute type I IFN 
treatment we used blood samples collected from patients with multiple sclerosis (MS) before 
and 18 hours after treatment with IFNβ (Avonex). By isolating major immune cell 
populations and performing gene expression analysis, we identified a T cell specific reduction 
of miR-31-5p and a monocyte specific reduction of miR-150-5p. Using IFNβ treated MS 
patients is a unique opportunity to study the type I IFN system in humans. It allowed us to 
study systemic regulation of miRNA in vivo to identify relevant miRNAs. To verify our 
findings, we treated blood samples from healthy donors with IFNβ and analyzed expression 
of miR-31-5p and miR-150-5p. However, only miR-31-5p was verified. A limitation of 
studying systemic regulation is that we were not able exclude that the monocyte specific 
reduction of miR-150-5p was caused by cell interactions extrinsic to monocytes. Due to the 
fast rate of IFNβ action, a shorter time interval than 18 hours might have proved more 
optimal to study direct regulation by IFNβ on specific cell types. Furthermore, we verified 
miR-31-5p reduction in T cells chronically exposed to IFNβ by collecting samples from 
patients with pSS and comparing to healthy controls. We concluded that miR-31-5p is 
reduced in T cells both after acute and chronic IFNβ exposure. 
To further understand what role miR-31-5p plays in modulating T cell activity, we explored 
publicly available data sets. Interestingly, analysis of gene expression data of T cells from 
miR-31-/- animals (GSE98615) identified altered expression of genes involved in energy 
metabolism, suggesting a role for miR-31-5p in metabolism. Previous studies have reported 
increased glycolysis in T cells from SLE patients (Yin et al., 2015). We hypothesized that 
miR-31-5p regulates metabolism in human T cells.  
To test our hypothesis, we transfected human T cells with a miR-31-5p inhibitor or a control 
inhibitor and measured metabolism. Indeed, we identified increased glycolysis in T cells with 
reduced miR-31-5p levels. Our data show that miR-31-5p negatively regulates metabolism in 
T cells. We can hypothesize that the reduced levels of miR-31-p caused by type IFNs in 
patients with autoimmune disease is driving increased metabolic rates. We also observed that 
addition of IFNα to CD4+ T cells increased the energy metabolism, a mechanism we 
hypothesize to be regulated via miR-31-5p reduction. However, the cells were only treated 
with IFNα for 24 hours prior to analysis and exhibited limited increases in glycolysis. In this 
project we were able to show that miR-31-5p regulated metabolism in CD4+ T cells but we 
can only hypothesize what role miR-31-5p plays in the type I IFN induced metabolic 
increases. Metabolism plays a major role in modulating T cells in immunity, it is possible that 
reduced levels of miR-31-5p contribute to autoimmunity by making autoreactive T cells less 
prone to exhaustion. 
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Figure 1. ECAR measured in CD4+ T cells upon miR-31 inhibition (left) and 24 hours of 
IFNα stimulation (right). 
 
4.2 PROJECT II: REVEALING IFNAR1 PROTEIN INTERACTIONS  
In project II we aimed to develop techniques to identify protein interactions of a 
transmembrane protein. Recent development in of proximity labeling techniques using 
bacterial biotin ligase (BirA) allows for protein labeling in living cells without the need to 
extract the protein of interest from the cell lysate, circumventing issues with solubilization of 
transmembrane proteins. In project II we used multiple variants of BirA to reveal protein 
interactions of the transmembrane receptor IFNAR1. 
Two different BirA ligases were used, modified from Aquifex aeolicus (BioID2) and human 
codon optimized Bacillus subtilis BirA (hBASU). We synthesized the two enzyme and 
compared their kinetics. hBASU showed significant labeling already after 1 minute of biotin 
exposure while no labeling was observed by BioID2. The standard range of labeling times for 
BioID2 is 16-24 hours (Roux et al., 2013), signifying a huge improvement in kinetics for the 
hBASU. The faster kinetics can be utilized to identify the rapid protein-protein interactions 
occurring downstream of IFNAR1 after IFNβ stimulation. The extended biotin exposure 
when using BioID2 also lead to a much larger portion of labeled proteins that can be 
classified as background, these are mainly protein interactions occurring during protein 
synthesis in the ribosome.  
We then cloned the cDNA sequence of IFNAR1 in to both BioID2 and hBASU vectors and 
performed quantitative mass spectrometry on labeled proteins. As expected the interactome 
using hBASU labeling was much smaller than that of BioID2, mainly due to the shorter 
incubation time with biotin. However, the two data sets generated an overlapping (>90%) set 
of interactors validating the two methods. In addition, we identified a number of IFN-
stimulated proteins (IFIT1, HERC5 and EIF2AK2) as interactors after stimulation with IFNβ 
further validating the system. Rather surprisingly we did not identify some of the known key 
interactors of IFNAR1 such as JAK1, TYK2 and IFNAR2. This could be explained by the 
design of the IFNAR1-BirA fusion protein, where we introduced a flexible linker between the 
proteins. It is possible that by doing so the BirA is out of range of the closest interactors. It is 
also possible that steric hindrance prohibits the enzyme to reach the closes interactors.   
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Interestingly, among the interactors we identified was a large number of nuclear proteins. 
This indicates that IFNAR1 translocates to the nucleus following stimulation, a claim that is 
supported by previous reports (Lubick et al., 2015; Subramaniam and Johnson, 2004). Many 
cell surface receptors are known to translocate to the nucleus suggesting that this might occur 
also during type I IFN signaling. 
In project II, we present methods to identify interactomes of challenging transmembrane 
proteins. Using these techniques, we successfully presented interactome data for IFNAR1. 
 
4.3 PROJECT III: IMQ INDUCES ER STRESS IN MELANOMA CELLS 
Moderate levels of ER stress have been shown to protect cancer cells from hypoxia. 
However, high levels of ER stress induce apoptosis of cancer cells and potentially provides 
an alternative route to target and kill tumors (Maurel et al., 2015). In project III, we screened 
a number of TLR and NOD agonists in melanoma cells to identify potent inducers of ER 
stress. TLR agonists have previously been shown to induce ER stress (Martinon et al., 2010). 
We used splicing of XBP1 to indicate ER stress and identified imiquimod (IMQ) as a potent 
ER stress inducer. We confirmed the findings by gene expression analysis of ER stress target 
genes. 
IMQ is known to induce type I IFNs via TLR7/TLR8 activation. However, melanoma cells 
do not express neither TLR7 or TLR8 indicating an alternative ER stress inducing 
mechanism. IMQ belongs to a group of small purine analogs referred to as 
imidazoquinolines. When studying properties of other purine containing molecules we 
verified that ATP is a potent inducer of cytosolic Ca2+  (Bandyopadhyay et al., 2000). Since 
depletion of Ca2+ from ER stores is known to induce ER stress (Mekahli et al., 2011), we 
hypothesized that IMQ induced ER stress through release of ER Ca2+. We measured Ca2+ 
influx by Fluo-3-AM. IMQ treatment of melanoma cells did indeed induce a rapid increase in 
cytosolic Ca2+. Ionomycin was used as a positive control. We tested imidazoquinolines RSQ 
and CL075 but none of them induced influx of Ca2+, further validating that IMQ act through a 
separate mechanism to TLR7. We also found that buffering extracellular Ca2+, or blocking 
calcium release activated channel (CRAC) Ca2+ channels, still led to release of ER Ca2+ 
stores and ER stress after IMQ treatment. It has long been believed that the anti-cancer effects 
of IMQ are driven by TLR-activation of tumor infiltrating immune cells, leading to 
production of IFNs and increased anti-tumor effects (Schon and Schon, 2007). While this 
might still be the case, our data suggest that IMQ also acts directly on cancer cells 
independent of immune cell activation. At this stage we concluded that IMQ triggers ER 
stress via release of Ca2+ from ER stores independently of TLR7 and TLR8. 
We hypothesized that IMQ bound an unknown cell surface receptor which induced release of 
ER Ca2+ and a secondary cytosolic Ca2+ influx. Since IMQ is a purine analog, we further 
hypothesized that it would bind a G protein-coupled receptor (GPCR). Similar to purines. By 
identifying the receptor, we aimed to possibly of design more specific and potent receptor 
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ligands that could potentially be used to target and kill melanoma cells. We decided to 
attempt genome-wide CRISPR/Cas9 screening using the GeCKO library to identify the 
receptor (Sanjana et al., 2014). Using transposon systems, we generated Cas9 expressing 
A375 cells and validated stable expression. We then introduced a genome-wide gRNA library 
and treated cells with IMQ, untreated cells were used as control. Surviving cells are 
sequenced by NGS and the gRNA work as a barcode to identify the perturbated gene 
underlying survival. We did not succeed in identifying surviving cell clones. During the 
course of the experiments we observed a rapid shift in pH of the culture medium causing all 
cells to die. The pH change occurred 4-5 days after addition of IMQ. We were not able to 
circumvent this issue. Instead, we devised a strategy to use the fluorescent properties of IMQ 
perform a FACS based screen. Unstained cells upon addition of IMQ and transduction of the 
gRNA library would represent a population of cell deficient in the IMQ binding receptor. 
 
Figure 2. Overview of the study design to identify an unknown IMQ receptor by genome 
wide-CRISPR/Cas9 screening. The genome-wide library of gRNAs are added to Cas9-
expressing A375 cells. Resistant cells are then sequenced and compared to control cells. 
In conclusion, we have identified that small molecule IMQ is a potent inducer of ER stress in 
melanoma cells through release of Ca2+, independently of TL7 and TLR8. Our data suggest 
that IMQ binds an unknown cell surface receptor that potentially could be targeted for 
therapeutic purposes.  
 
4.4 PROJECT IV: TRIM28 DRIVES A PHENOTYPIC SWITCH IN MELANOMA 
BY CONTROLING JUNB EXPRESSION 
During metastatic progression in malignant melanoma, unlike epithelial cancers such as 
breast cancer, cells typically do not undergo canonical EMT. It has become apparent that 
melanoma cells are prone to phenotype switching, and the plasticity is seemingly not driven 
Pooled lentiviral 
CRISPR library
A375Cas9 cells
Mutated pool of A375Cas9 cells
Resistant cells Control cells
Puromycin selection
(MOI = 0.3)
+IMQ w/o IMQ
NGS
(Illumina MiSeq/HiSeq)
NGS
(Illumina MiSeq/HiSeq)
U6 sgRNA
300 bpPCR
U6 sgRNA
300 bpPCR
 26 
by mutations (Brinckerhoff, 2017; Cheli et al., 2014; Croteau et al., 2013; Falletta et al., 
2017; Hoek et al., 2008; Kim et al., 2017). We hypothesized that metastatic progression in 
malignant melanoma is driven by transcriptional regulation of a phenotype switch. Therefore, 
we set out to identify which transcriptional regulators were controlling this switch and the 
underlying mechanisms.  
In an attempt to identify genes associated to metastatic progression of melanoma, we 
analyzed RNA-seq data from 367 metastatic melanoma patients available from The Cancer 
Genome Atlas (TCGA). By performing Principle Component Analysis (PCA) and 
partitioning around medoids clustering we identified two clusters of patients, cluster 1 (C1) 
and cluster 2 (C2). Survival analysis of these patient clusters revealed that patients in C2 had 
significantly shorter overall survival. We identified a strong repression of BRDs in cluster 
C2. Interestingly, four BRDs were instead significantly upregulated in C2 compared to C1; 
BRPF1, BRD4, SMARCA4 and TRIM28. We were intrigued by the BRD signature since 
BRDs are epigenetic regulators that are highly involved in cancers (Andrieu et al., 2016; 
Fujisawa and Filippakopoulos, 2017; Jain and Barton, 2017) and comprise a family of 
proteins that can be targeted therapeutically (Filippakopoulos et al., 2010). Amongst the four 
upregulated genes TRIM28 was the most upregulated in C2. Survival analysis based on 
TRIM28 high or low expression showed significantly shorter survival for stage III melanoma 
patients with high TRIM28 expression. Previous studies have highlighted the importance of 
TRIM28 multiple cancer forms (Fong et al., 2018; Li et al., 2017; Wei et al., 2016). At this 
stage we hypothesized that TRIM28 was the discriminating factor of C2 and furthermore was 
a driving factor for metastatic progression of disease.  
 
 
 
 
 
Figure 3. PCA plot of 367 melanoma patients showing C1 in blue and C2 in red (left). 
Heatmap of BRD genes showing BRD signature in C2 (right).  
To test this hypothesis TRIM28 KD cells were generated. We identified a repressed 
metastatic gene signature (Winnepenninckx) in TRIM28 KD cells as well as a repressed 
YAP1 signature. YAP1 is a part of Hippo signaling that control cell homeostasis and organ 
growth during development (Piccolo et al., 2014). Previous reports link YAP1 to the 
development of melanoma metastases (Lamar et al., 2012; Nallet-Staub et al., 2014) and 
taken together with the reduced metastatic signature we hypothesized that TRIM28 drives 
expression of important metastatic gene signatures. By performing intravenous xenograft 
engraftments in to BALBc nu/nu animals we identified that TRIM28 KD cells colonized 
significantly less in the lung compared to NTC cells. We also observed that TRIM28 KD cells 
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were significantly less invasive in vitro compared to control cells. We were able to show that 
TRIM28 regulates expression of metastatic gene signatures and that TRIM28 is necessary for 
invasiveness and colonization of melanoma cells. 
Interestingly, we also observed increased MAPK signatures in TRIM28 KD cells, 
independent of ERK1/2 phosphorylation. Amongst the genes upregulated were CXCL8 and 
CXCL1. We were surprised because MAPK signaling and CXCL8 expression is associated to 
increase tumor growth (Liu et al., 2016a). No increase in pERK1/2 was observed, based on 
these results we hypothesized that regulation of MAPK signature genes occurred at 
transcriptional level. Upon subcutaneous xenograft engraftments, we observed significantly 
increased tumor growth in TRIM28 KD cells. This data was in concurrence with the MAPK 
data. These results were surprising since TRIM28 reduction has been associated to reduced 
tumor growth in breast cancer and prostate cancer (Fong et al., 2018; Li et al., 2017; Wei et 
al., 2016). We hypothesize that the increased tumor growth is driven by pro-tumorigenic 
factors such as CXCL8. It is possible that epithelial cancers respond differently to CXCL8 or 
that TRIM28 acts via a mechanism specific for melanoma cells. These results further 
elucidate the differences between epithelial cancers and malignant melanoma.  
To identify the mechanisms underlying TRIM28 regulation of MAPK and YAP1 signatures 
we established the TRIM28 interactome in melanoma cells using BioID proximity 
proteomics (Roux et al., 2012). Our initial hypothesis was that TRIM28 interacts with 
components of Hippo or MAPK signaling thereby altering the activity of YAP1. However, no 
known interactors involved in either YAP1 or MAPK signaling were identified. Instead, we 
identified several key components of the RNAPII-pause complex including CD9, CDK11, 
CDK12 and HEXIM1. Previous reports identified TRIM28 as a part of the RNAPII-pause 
complex, but the studies reported conflicting mechanisms (Bunch et al., 2014; McNamara et 
al., 2016). The study by McNamara et al. identified TRIM28 as a recruiter for the RNAPII 
initiation complex, while the study by Bunch et al. identified TRIM28 as a negative regulator 
of RNAPII transcriptional initiation. To elucidate the role of TRIM28 in RNAPII-pausing in 
melanoma we combined ChIP-qPCR with analysis of ChIP-seq data. Global ChIP signals of 
TRIM28, CDK9 and HEXIM1 overlapped to a great degree, indicating co-occupancy at TSS. 
By ChIP-qPCR, we confirmed TRIM28 as a negative regulator of RNAPII pausing on the 
JUNB and FOSL1 genes.  
The role and function of TRIM28 on the RNAPII-pausing complex seem similar to that of 
BRD4 (Patel et al., 2013). However, BRD4 is not identified as an interacting partner to 
TRIM28 in our BioID experiments. It is possible that TRIM28 and BRD4 are mutually 
exclusive in their functions and regulate separate sets of genes, both through the RNAPII-
pause complex. It leads to an interesting question whether or not KD of BRD4, or inhibition 
by JQ-1, in melanoma cells induce a similar phenotypic switch as KD of TRIM28. 
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Figure 4. Overlap of ChIP-seq signals from TRIM28, CDK9 and HEXIM1 (left). Pause index 
on JUNB and FOSL1 in control SCRAMBLED control cells and TRIM28 KD cells (right). 
FOSL1 and JunB are both part of the AP-1 transcription factor complex which acts 
downstream of ERK1/2 in the MAPK signaling cascade. This led us to hypothesize that 
increased levels of JunB and FOSL1 after TRIM28 KD explained the observed increase in 
expression of MAPK signature genes. In addition, FOSL1 has been to shown interact with 
TEAD4 and activate transcription of YAP1 target genes (Liu et al., 2016b; Zanconato et al., 
2015). Since we observed decreased expression of YAP1 target genes, we instead 
hypothesized that JunB simultaneously drove the expression of MAPK signatures (including 
CXCL8 expression) and suppressed the expression of YAP1 target genes.  
We generated JUNB overexpressing cells and indeed they had strongly repressed expression 
of YAP1 target genes expression as well as increased CXCL8 expression. In contrast, when 
overexpressing FOSL1 we observed increased YAP1 target gene expression as expected but 
no differences in CXCL8 expression.  
In conclusion, we have demonstrated that TRIM28 is a negative regulator of RNA-pausing. 
TRIM28 regulates expression of JUNB through RNAPII-pausing and increased expression of 
JUNB in melanoma leads to a phenotype switching.  
 
Figure 5. Proposed model of the role of TRIM28 in RNAPII pausing. TRIM28 interacts with 
CDK9 and HEXIM1 of the RNAPII pausing complex. KD of TRIM28 releases the pause 
complex and induces JUNB transcription. 
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Figure 6. Proposed model by which JunB inhibits the expression of TEAD4 activated genes 
while activating CXCL8 expression. JunB expression leads to a phenotypic switch in 
melanoma cells. 
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5 FUTURE PERSPECTIVES 
How does regulation of T cell metabolism contribute to T cell function? 
After discovering suppressed levels of miR-31-5p in T cells of patients with pSS, as well as 
in patients treated with IFNβ, we found that miR-31-5p negatively regulates the energy 
metabolism of CD4+ T cells. It remains to elucidate if this mechanism contributes to 
autoimmune diseases and if this mechanism can be targeted in any way to reduce disease 
burden. This finding also suggests that reduced miR-31-5p levels during chronic type I IFN 
exposure serves to avoid T cell exhaustion. This could potentially be a mechanism both in 
systemic autoimmune diseases and chronic viral infections. Indeed, miR-31 knockout CD8+ 
T cells respond better to viral infections with reduced signs of exhaustion (Moffett et al., 
2017). 
 
Does IFNAR1 translocate to the nucleus and is it of functional importance? 
By developing a method to identify protein interactions of transmembrane proteins we were 
able to generate a protein interactome for IFNAR1. By analyzing the interactome data we 
identified a number of unexpected nuclear proteins upon receptor activation. This suggest that 
IFNAR1 translocate to the nucleus upon activation. However, at this stage we lack definitive 
proof that nuclear translocation occurs.  
If what we identified is true, the major question is whether or not nuclear translocation of 
IFNAR1 has functional implications to the cell. Many receptors are known to translocate to 
the nucleus with functional implication. It is possible that nuclear translocation of IFNAR1 
signify additional features of the type I IFNA system not yet known to researchers. The role 
of the type I IFN system in autoimmune disease is poorly understood. IFNAR1 nuclear 
translocation represents an exciting question that could contribute further to our 
understanding of the diseases. 
 
Can we use IMQ as a model to develop ER stress-inducing cancer therapies? 
We show that IMQ trigger ER stress in cancer cells independently of TLR7 and TLR8. By 
doing so inducing cell death. We also show that IMQ in fact bind to the cell surface of 
melanoma cells despite lack of TLR7/TLR8 expression. The challenge moving forward will 
be to identify cell surface receptors able to induce ER stress. In doing so researchers might be 
able to engineer ligands targeting the specific receptor to induce cell death via ER stress. We 
attempted to identify the receptor by performing genome-wide perturbation screens with 
moderate success. It is important to ask whether or not the effects observed are caused by a 
single receptor or mechanism, or whether IMQ acts on multiple pathways triggering ER 
stress in cells. By performing smaller screens against selected targets such as cell surface 
receptors only, we ca reduce background in the experiments and can study exactly what we 
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are looking for. Increasing chances of determining the exact ER stress inducing mechanisms 
by IMQ. 
 
Is TRIM28 a suitable target to treat patients with metastatic melanoma? 
We have identified that TRIM28 is a regulator of a phenotypic switch in melanoma cells that 
regulate invasiveness and growth of melanoma cells. The major questions are now whether or 
not this mechanism can be targeted therapeutically and if it would be beneficial for patients. 
TRIM28 contains a BRD and is part of the BRD protein family. Many inhibitors targeting 
BRDs are currently being developed and evaluated by academic researcher groups and the 
pharmaceutical industry. Typical BRDs bind acetylated lysine through a structure referred to 
as a Z-loop that contains two tyrosine residues and a more distal asparagine residue. 
Researchers have taken advantage of this binding pocket to develop a range of BRD 
inhibitors with specificity towards different classes of BRDs. However, TRIM28 belongs to a 
class of atypical BRD proteins. The BRD of TRIM28 does not contain the critical tyrosine 
and asparagine residues commonly used to develop inhibitors against and is therefore 
unaffected by existing BRD inhibitors. 
To develop an inhibitor against TRIM28 we must first study the binding pocket of TRIM28 
in order to identify inhibitors that can possibly bind and inhibit TRIM28. This represent a 
major future challenge. An alternative approach would be to inhibit other proteins in the 
RNAPII pausing complex such as CDK9. Inhibitors for CDK9 are currently in clinical trials 
(Morales and Giordano, 2016). However, specificity of current CDK-inhibitors is an issue.  
The second question is whether or not targeting TRIM28 would be beneficial for patients. As 
we have shown, metastatic melanoma patients with high expression of TRIM28 have a 
shorter survival. We have also shown that TRIM28 drives a metastatic phenotype of 
melanoma cells. We reason that targeting of TRIM28 would limit metastatic progression of 
the disease which could prolong survival of melanoma patients. However, in addition to the 
discovery that reduced levels of TRIM28 limited the metastatic capabilities of melanoma 
cells, we also identified that proliferation increased. This means that targeting TRIM28 as a 
therapy might lead to increased growth of existing tumors. Because the metastatic 
progression of melanoma to distal organs represent the major cause of death for melanoma 
patients, therapies that specifically target the metastatic progression is of great need. 
Therefore, TRIM28 could be targeted to specifically inhibit metastatic progression in 
combination with pre-existing treatment options. 
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